79 results about "Anti inflammatory treatment" patented technology

A method for laser anti-inflammatory treatment of painful symptomatologies and for tissue regeneration includes generating a pulsed laser beam with laser at a wavelength between 0.75 and 2.5 micrometers. The laser energy is conveyed to a hand unit where the laser beam is preferably defocused. The operator then applies the defocused laser beam the skin of a patient in need of treatment. The average power density per pulse of the defocused laser beam on the skin being 8 W / cm2 per pulse or more.

Compounds and methods for use in immunosuppressive and anti-inflammatory treatment are described. The compounds are triptolide analogs with improved water solubility and low toxicity.

A method for laser anti-inflammatory treatment of painful symptomatologies and for tissue regeneration includes generating a pulsed laser beam with laser at a wavelength between 0.75 and 2.5 micrometers. The laser energy is conveyed to a hand unit where the laser beam is preferably defocused. The operator then applies the defocused laser beam the skin of a patient in need of treatment. The average power density per pulse of the defocused laser beam on the skin being 8 W / cm2 per pulse or more.

The present invention relates to an improved method for treating a wide range of inflammatory disorders by administering a tetracycline compound together with an effective inhibitor of tetracycline absorption, such as polyvalent metals. Pharmaceutical compositions used in that method are also taught.

The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumor and / or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases. In a fifth aspect, the present invention relates to the use of a pharmaceutical composition comprising said water soluble curcumin derivatives in the treatment of cancer and inflammatory diseases and to a new pharmaceutical composition comprising said water soluble curcumin derivatives.

The invention belongs to the technical field of medicines and discloses new diarylheptanoid compounds extracted and separated from Guangxi curcuma zedoary and application thereof in the field of medicines. The chemical structure of the diarylheptanoid compounds is determined by spectrum technology such as a high resolution mass spectrum, one-dimensional and two-dimensional nuclear magnetic resonance spectrum and the like, and a chemical method. The diarylheptanoid compounds can be combined with a pharmaceutically acceptable carrier to prepare clinically acceptable medicines for anti-inflammatory treatment. Experiments for inhibiting lipopolysaccharide-induced rat macrophage from synthesizing nitric oxide (NO) in vitro prove that: the diarylheptanoid compounds have high activity of inhibiting the nitric oxide from being generated, and can be used as anti-inflammatory medicines for preventing and / or treating human and animals.

There is provided a composition for anti-cancer or anti-inflammatory treatment having an effective amount of N-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding N-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating disease by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3, its homologues, antibody to galectin-3 carbohydrate binding sites, or a nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Further, there is provided a disease treatment having an effective amount of N-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding N-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier.

The invention discloses isobenzazole compounds derived from marine fungi, a preparation method of the isobenzazole compounds and application of the isobenzazole compounds in the preparation of anti-inflammatory drugs. The structural formulae of the isobenzazole new compounds are represented by a formula I, II, III or IV. The new compounds are capable of remarkably inhibiting the generation of LPS-induced NO and can be used for preparing the anti-inflammatory drugs, and the IC50 of the compounds are respectively 8.9mM(I), 12.4mM(II), 18.2mM(III) and 22.7mM(IV). Therefore, the isobenzazole compounds have the clinical application potential in the anti-inflammatory treatment.

Methods and materials are provided for induction-maintenance regimens of targeted anti-inflammatory therapies (TATs) for treatment of a variety of diseases and disorders. Preferred embodiments include administration of one or more TATs using an induction regimen comprising a lower dose per administration administered by a more invasive and / or more localized route, followed by administration of one or more TATS using a maintenance regimen, comprising a higher dose per administration administered by a less invasive and / or less localized route.

The invention discloses an Excoecaria agallocha endophytic fungus sourced indene derivative, and applications thereof in preparation of anti-inflammatory drugs. The Excoecaria agallocha endophytic fungus sourced indene derivative is obtained via separation from Excoecaria agallocha endophytic fungus Diaporthe sp.SYSU-HQ3, the Excoecaria agallocha endophytic fungus Diaporthe sp.SYSU-HQ3 is preserved at Guangdong Microbial Culture Collection Center on 4th, August, 2017, and the preservation number is GDMCC No:60217. The Excoecaria agallocha endophytic fungus sourced indene derivative is capableof inhibiting generation of LPS induced NO obviously, possesses clinical application potential in anti-inflammatory treatment, can be used for preparing anti-inflammatory drugs, and is promising in application prospect, the IC<50> is 8.5mM(1), 5.9mM(2), 4.2mN(3), and 4.2mM(4).

The present invention makes it possible to enhance steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment, by administering an effective amount of an oligonucleotide having the sequence 5′-Xm-TTCGT-Yn-3′ to 5 said patient, wherein X is A, T, C or G, Y is A, T, C or G, m=0-7, n=0-7 and wherein at least one CG dinucleotide is unmethylated. The invention also encompasses the use of said oligonucleotide for the manufacture of pharmaceuticals.

The invention belongs to the technical field of pharmaceutical compounds, and particularly discloses a di-sesquiterpene compound derived from marine fungi, a preparation method of the di-sesquiterpenecompound and application of the di-sesquiterpene compound in preparation of anti-inflammatory drugs. The structural formula of the di-sesquiterpene compound is shown in formulas I, II and III, and the di-sesquiterpene compound is prepared by fermenting marine fungus Aspergillus sp. ZJ-68, wherein the marine fungus Aspergillus sp. ZJ-68 was preserved in Guangdong Culture Collection Center on Jan.21, 2019 with the preservation number of GDMCC No: 60541; the production of NO induced by LPS can be significantly inhibited by compounds I, II, and III, specifically, IC50 is 16.48 micrometer, 20.7 micrometer and 24.4 micrometer, respectively, and the IC50 of the positive control indomethacin was 37.5 micrometer. Therefore, the di-sesquiterpene compound can be used for preparing the anti-inflammatory drugs and has the clinical application potential of anti-inflammatory treatment.

The invention relates to the field of drug research and development and particularly discloses an application of a compound HUBIN-1 in preparation of a drug for preventing and / or treating liver inflammatory diseases. Extensive and deep research discovers the hepatocyte protection function and the anti-inflammatory treatment function of the compound HUBIN-1 for the first time, the compound HUBIN-1 is applicable to various types of liver inflammations, and the application field of the compound HUBIN-1 is broadened. The novel drug for preventing and / or treating various liver inflammatory diseases such as acute hepatitis, chronic hepatitis and severe hepatitis (hepatic failure) which include viral hepatitis, drug-induced hepatitis, nonalcoholic fatty liver disease, alcoholic hepatitis, autoimmune hepatitis and the like is provided and has remarkable social benefits.

The invention relates to an injectable self-curing artificial bone repair material and a preparation method thereof. The preparation method comprises the following steps: preparation of two-phase calcium phosphate porous particles, preparation of mineralized collagen porous calcium phosphate composite material and mixing with calcium sulfate hemihydrate. The prepared artificial bone repair material has the following characteristics that: (a) the mineralized collagen is uniformly distributed on the surface and the pores of the two-phase calcium phosphate porous particles, so that the mineralized collagen is uniformly combined with the porous calcium phosphate, thereby having better biocompatibility; (b) the material has a porous structure, not only is favorable for the growth of the bone tissue and the creeping substitution, but also has certain supporting strength; (c) the material can be used as a carrier for growth factors and various antibiotics to carry out anti-inflammatory treatment; (d) the material can be developed under X-ray, which facilitates inspection; (e) the material is degradable, which avoids secondary pain resulting from taking out, and the rate of degradation maybe matched with the new bone growth rate; (f) the material can be injected in situ and has excellent self-curing properties.

The present invention makes it possible to enhance steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment, by administering an effective amount of an oligonucleotide having the sequence 5'-Xm-TTCGT-Yn-3' to 5 said patient, wherein X is A, T, C or G, Y is A, T, C or G, m=0-7, n=0-7 and wherein at least one CG dinucleotide is unmethylated. The invention also encompasses the use of said oligonucleotide for the manufacture of pharmaceuticals.

Compounds useful in immunosuppressive and anti-inflammatory treatment are described. The compounds are hydrolyzable triptolide analogs with improved water solubility and generally lower toxicity than the parent compound.

The invention discloses a marine fungus-derived naphthoquinone compound and anti-inflammatory application thereof. A marine fungus Diaporthe sp.GZU-1021 is obtained through separation and purification, and preserved in the Guangdong General Microbiological Culture Collection Center (GDMCC), and the preservation number is GDMCC No: 60601. The strain can secrete the brand-new naphthoquinone compound, and the compound has the effect of remarkably inhibiting generation of LPS-induced NO and has the clinical application potential for anti-inflammatory treatment. Therefore, the naphthoquinone compound has good application prospects and wide development space in preparation of anti-inflammatory drugs.

A method and composition for treating osteoarthritis including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. Ethyl (α-guanido-methyl) ethanoate provides a safe, non-toxic anti-inflammatory treatment for osteoarthritis.

The invention discloses an aspirin-based carbon quantum dot and application thereof in aspects of cell imaging and anti-inflammatory treatment, belonging to the technical field of nano-drugs. The invention in particular relates to a carbon quantum dot with strong fluorescent properties prepared from a hydrazine hydrate solution by utilizing a microwave heating method under the condition that aspirin dissolution is promoted. The carbon quantum dot prepared by the method is very stable under hyper-salt concentration and physiological pH conditions, blue-fluorescence is maintained, the carbon quantum dot can enter the cell nucleus, and the cells are effectively traced; and meanwhile, the original anti-inflammatory effect of aspirin is remained, and inflammatory cells can be effectively inhibited in an acute inflammation model constructed by utilizing carrageenin. In addition, the prepared aspirin carbon quantum dot is low in toxicity and does not influence liver and kidney functions and organs such as the heart, liver, spleen and kidney in in-vivo application, and the aim that the nanometer material has dual effects of diagnosis and treatment can be achieved.

The present invention relates to gene markers associated with a method for predicting the clinical response in a patient suffering from an inflammatory diseases or disorders to an anti-inflammatory treatment.

The invention relates to eye drops for treating conjunctivitis, which have the effect of treating the conjunctivitis by washing eyes to achieve anti-inflammatory treatment. The eye drops for treating the conjunctivitis are the externally applied eye drops which are prepared from the following traditional Chinese medicine raw materials: 13-17 parts of common jujube bark, 13-17 parts of mulberry bark, 8-12 parts of herb of ramose scouring rush, 8-12 parts of swordlike atractylodes rhizome, 10-14 parts of chrysanthemum and 8-12 parts of feather cockscomb seed. According to the invention, 319 patients (408 eyes) with the acute conjunctivitis in a group are observed after being subjected to conjunctival sac washing treatment with the eye drops disclosed by the invention so that the eye drops are proved to have significant curative effects against acute bacterial conjunctivitis.

The invention discloses a making method of specific crystal type of 5-(4-chlorine-phenyl)-N-hydroxy-1-(4-methoxy-phenyl)-N-methyl-1H-pyrazole-3-propionamide (Tepoxalin), which is inhibitor of epoxy oxygenase and lipoxidas in the arachidonic acid cascading reaction.

The invention discloses seven withanolides compounds derived from cape gooseberries as well as a preparation method and application of the withanolides compounds, and relates to structures of five new(1-5) and two known (6-7) withanolides compounds in the cape gooseberries, a preparation method of the withanolides compounds and application of the withanolides compounds in anti-inflammatory and neurodegenerative disease treatment medicines. The compounds (2-4, 6, 7) provided by the invention have good NO inhibition activity, and can be used for development and application of anti-inflammatoryand neurodegenerative disease treatment drugs.

Model and method of treating inflammatory diseases. Traditional treatments for such diseases include administering to the patient toxic anti-inflammatory drugs. Following stabilization of the symptoms, the drug doses are tapered down to minimize side effects, as a result of which inflammation remains high and the disease is rarely cured. A chemistry-based disease model concludes that irrespective of the role that inflammation plays in the disease, inflammation reduction will impede disease initiation and progression. Managing and controlling inflammatory diseases requires reducing inflammation to acceptable normal values. Non-toxic ways such as non-steroidal anti-inflammatory drugs, anti-inflammatory diets, and regular exercise allow such reduction in inflammation to normal values, thereby slowing down or arresting disease progression and allowing the discontinuation or reduction of toxic anti-inflammatory therapy while maintaining low inflammation using non-toxic therapy.

Methods for enhancing steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition who does not respond or responds poorly or inadequately to steroid anti-inflammatory treatment or a steroid dependent patient afflicted with an inflammatory condition and currently on steroid anti-inflammatory treatment who shows an inability to be weaned off systemic or topical administered steroid treatment comprise administering an oligonucleotide having the sequence 5′-Xm-CG-Yn-3′ wherein X is A, T, C, or G, Y is A, T, C, or G, m is 1-20 and n is 1-20, or the sequence 5′-CG-3′ and from 8 to 40 nucleotides, wherein at least one CG dinucleotide is unmethylated. The oligonucleotide is administered in an amount effective to improve sensitivity of the patient to the steroid anti-inflammatory treatment and thereby induce a clinical response in the steroid refractory patient or improve a clinical response in the steroid dependent patient.

The invention relates to structures of five new ent-atisane diterpenoid compounds (1-5), a preparation method and application of the five new ent-atisane diterpenoid compounds (1-5) in anti-inflammatory and neurodegenerative disease treatment drugs. The new compounds (1-5) have the following structures as shown in the specification. The five new compounds provided by the invention have NO inhibition and nerve axon growth promotion activity, and can be used for development and application of anti-inflammatory and neurodegenerative disease treatment drugs.